Oncotarget

Research Papers:

The survival benefits of local surgery in stage IV breast cancer are not affected by breast cancer subtypes: a population-based analysis

San-Gang Wu, Wen-Weng Zhang, Jia-Yuan Sun, Feng-Yan Li, Huan-Xin Lin, Juan Zhou _ and Zhen-Yu He

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:67851-67860. https://doi.org/10.18632/oncotarget.18889

Metrics: PDF 610 views  |   HTML 982 views  |   ?  


Abstract

San-Gang Wu1,*, Wen-Weng Zhang2,*, Jia-Yuan Sun2, Feng-Yan Li2, Huan-Xin Lin2, Juan Zhou3 and Zhen-Yu He2

1Department of Radiation Oncology, Xiamen Cancer Hospital, The First Affiliated Hospital of Xiamen University, Xiamen 361003, People’s Republic of China

2Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou 510060, People’s Republic of China

3Department of Obstetrics and Gynecology, The First Affiliated Hospital of Xiamen University, Xiamen 361003, People’s Republic of China

*These authors have contributed equally to this work

Correspondance to:

Juan Zhou, email: juanzhou12345@163.com

Zhen-Yu He, email: hezhy@sysucc.org.cn

Keywords: breast cancer, SEER program, surgery, subtype, survival

Received: February 20, 2017     Accepted: June 04, 2017     Published: June 29, 2017

ABSTRACT

This retrospective study aimed to investigate the clinical value of local surgery in stage IV BC and determined whether the survival outcomes were affected by the breast cancer subtype (BCS). Women with de novo stage IV BC from 2010 to 2013 were included using the Surveillance Epidemiology and End Results database. Univariate and multivariate Cox regression analyses were performed to evaluate the prognostic factors for breast cancer-specific survival (BCSS) and overall survival (OS). Among 9,256 patients were identified, 3,130 (33.8%) were received local surgery. Patients with hormone receptor (HR)+/human epidermal growth factor receptor 2 (HER2)- subtype were less likely to receive local surgery, while HR-/HER2- tumors were more likely to receive surgery. Multivariate analyses revealed that local surgery improved survival, surgical intervention was an independent favorable prognostic factor for BCSS (P < 0.001) and OS (P < 0.001). Patients who receipt of surgery had better survival outcomes compared with the non-surgery group, and the survival benefits of local surgery were not affected by the BCS status. Local surgery was improved survival for patients with stage IV BC regardless of the BCS status.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18889